Sandoz, with healthcare professionals across the Cancer Vanguard, has developed an education and engagement programme about the use of biosimilar medicines. These drugs are highly similar copies of biologic medicines and offer significant potential savings.
Most medicines are relatively simple and easy to produce and copy and the resulting copies are known as generic medicines. Biologic medicines are manufactured in a living system such as a microorganism, or plant or animal cells, and are more complicated to produce and copy. The copies are highly similar, rather than identical, and are called biosimilars.
This programme aims to improve healthcare professionals’ understanding of biosimilars and help them to better inform patients about their use and assist in their timely introduction when appropriate.
A process timeline for adoption has been developed with accompanying guidance, resources and template documents to support the NHS to enhance biosimilar uptake.
For more information please contact Jatinder Harchowal.
Find out more about the Biosimilars programme and access resources.